DE69232497D1 - Behandlung von krankheiten durch ortsspezifische instillation von zellen oder ortsspezifische transformation von zellen sowie ausrüstung dafür - Google Patents

Behandlung von krankheiten durch ortsspezifische instillation von zellen oder ortsspezifische transformation von zellen sowie ausrüstung dafür

Info

Publication number
DE69232497D1
DE69232497D1 DE69232497T DE69232497T DE69232497D1 DE 69232497 D1 DE69232497 D1 DE 69232497D1 DE 69232497 T DE69232497 T DE 69232497T DE 69232497 T DE69232497 T DE 69232497T DE 69232497 D1 DE69232497 D1 DE 69232497D1
Authority
DE
Germany
Prior art keywords
cells
treatment
diseases
proteins
specific transformation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69232497T
Other languages
English (en)
Other versions
DE69232497T2 (de
Inventor
G Nabel
J Nabel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
Original Assignee
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27110984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69232497(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Michigan filed Critical University of Michigan
Publication of DE69232497D1 publication Critical patent/DE69232497D1/de
Application granted granted Critical
Publication of DE69232497T2 publication Critical patent/DE69232497T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A61B2017/22082—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for after introduction of a substance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A61B2017/22082—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for after introduction of a substance
    • A61B2017/22084—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for after introduction of a substance stone- or thrombus-dissolving
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/254—Enzymes, proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/256—Antibodies, e.g. immunoglobulins, vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/64—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
    • A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Medical Informatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
DE69232497T 1991-06-28 1992-06-26 Behandlung von krankheiten durch ortsspezifische instillation von zellen oder ortsspezifische transformation von zellen sowie ausrüstung dafür Expired - Fee Related DE69232497T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72450991A 1991-06-28 1991-06-28
US07/741,244 US5328470A (en) 1989-03-31 1991-07-26 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
PCT/US1992/005242 WO1993000051A1 (en) 1991-06-28 1992-06-26 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor

Publications (2)

Publication Number Publication Date
DE69232497D1 true DE69232497D1 (de) 2002-04-25
DE69232497T2 DE69232497T2 (de) 2002-11-14

Family

ID=27110984

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69232497T Expired - Fee Related DE69232497T2 (de) 1991-06-28 1992-06-26 Behandlung von krankheiten durch ortsspezifische instillation von zellen oder ortsspezifische transformation von zellen sowie ausrüstung dafür
DE1213032T Pending DE1213032T1 (de) 1991-06-28 1992-06-26 Behandlung von Krankheiten durch ortsspezifische Instillation von Zellen oder ortsspezifischer Transformation von Zellen sowie Ausrüstung dafür

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE1213032T Pending DE1213032T1 (de) 1991-06-28 1992-06-26 Behandlung von Krankheiten durch ortsspezifische Instillation von Zellen oder ortsspezifischer Transformation von Zellen sowie Ausrüstung dafür

Country Status (9)

Country Link
US (1) US5328470A (de)
EP (4) EP1927368A3 (de)
JP (3) JP3712409B2 (de)
AT (2) ATE385810T1 (de)
CA (1) CA2112376A1 (de)
DE (2) DE69232497T2 (de)
DK (1) DK0591385T3 (de)
ES (1) ES2301602T3 (de)
WO (1) WO1993000051A1 (de)

Families Citing this family (585)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5575815A (en) * 1988-08-24 1996-11-19 Endoluminal Therapeutics, Inc. Local polymeric gel therapy
US5328471A (en) * 1990-02-26 1994-07-12 Endoluminal Therapeutics, Inc. Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens
US5843156A (en) * 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
US5843089A (en) * 1990-12-28 1998-12-01 Boston Scientific Corporation Stent lining
US5674192A (en) * 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
EP0575518A1 (de) 1991-03-06 1993-12-29 Board Of Regents, The University Of Texas System Verfahren und zusammensetzungen fuer die selektive hemmung von genexpression
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US6743623B2 (en) * 1991-09-27 2004-06-01 Centre National De La Recherche Scientifique Viral recombinant vectors for expression in muscle cells
US5586982A (en) 1992-04-10 1996-12-24 Abela; George S. Cell transfection apparatus and method
US6936025B1 (en) 1992-05-19 2005-08-30 Bacchus Vascular, Inc. Thrombolysis device
US5713848A (en) 1993-05-19 1998-02-03 Dubrul; Will R. Vibrating catheter
US6806084B1 (en) * 1992-06-04 2004-10-19 The Regents Of The University Of California Methods for compositions for in vivo gene delivery
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
EP0746625B1 (de) 1992-11-09 2004-03-31 THE UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Erzielbare vektorenpartikel
GB9223816D0 (en) 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
WO1994011506A1 (en) * 1992-11-18 1994-05-26 Arch Development Corporation Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
US5658565A (en) * 1994-06-24 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inducible nitric oxide synthase gene for treatment of disease
US5830461A (en) * 1992-11-25 1998-11-03 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods for promoting wound healing and treating transplant-associated vasculopathy
US5658780A (en) 1992-12-07 1997-08-19 Ribozyme Pharmaceuticals, Inc. Rel a targeted ribozymes
WO1994026915A1 (en) * 1993-05-10 1994-11-24 The Regents Of The University Of Michigan Gene transfer into pancreatic and biliary epithelial cells
AU7019494A (en) * 1993-05-20 1994-12-20 Baylor College Of Medicine Genetic therapy for cardiovascular disease
EP1624068A1 (de) * 1993-06-01 2006-02-08 Life Technologies Inc. Genetische Impfung mit kationischen Lipidstoffen
AU7404994A (en) * 1993-07-30 1995-02-28 Regents Of The University Of California, The Endocardial infusion catheter
US6682728B1 (en) * 1993-10-13 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Efficient and selective adenoviral-mediated gene transfer into vascular neointima
ES2077519B1 (es) * 1993-11-22 1996-07-01 Fernandez De Lomana Euge Anaya Cateter intraaortico para perfusion y conservacion renal.
US5792106A (en) * 1993-12-02 1998-08-11 Scimed Life Systems, Inc. In situ stent forming catheter
US5409012A (en) * 1993-12-30 1995-04-25 Boston Scientific Corporation Sample collection using catheter with expandable member
WO1995018856A1 (en) 1993-12-30 1995-07-13 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing hedgehog-like proteins
DE4411402A1 (de) * 1994-03-31 1995-10-05 Juergen Schrader DNA-Expressionsvektoren zur Verwendung in der gentherapeutischen Behandlung von Gefäßerkrankungen
WO1995027494A1 (en) * 1994-04-11 1995-10-19 Sloan-Kettering Institute For Cancer Research DEFECTIVE HERPES AND DEFECTIVE ADENO-ASSOCIATED VIRUS VECTORS WITH p53 FOR THE TREATMENT OF CANCER
US6103890A (en) * 1994-05-18 2000-08-15 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids that cleave C-fos
US6150137A (en) 1994-05-27 2000-11-21 Ariad Pharmaceuticals, Inc. Immunosuppressant target proteins
FR2723697B1 (fr) * 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa Methode de traitement de la restenose par la therapie genique
NO180167C (no) * 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
US6911216B1 (en) 1994-10-12 2005-06-28 Genzyme Corporation Targeted delivery via biodegradable polymers
AU700903B2 (en) * 1994-10-12 1999-01-14 Focal, Inc. Targeted delivery via biodegradable polymers
US5713861A (en) * 1994-10-17 1998-02-03 Vanarthos; William Trauma urethral catheter and method of using same
US5641665A (en) * 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression
US5948767A (en) * 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
WO1996020208A2 (de) * 1994-12-28 1996-07-04 Max-Delbrück-Centrum für Molekulare Medizin Neues cholesterolderivat für den liposomalen gentransfer
WO1996020731A1 (en) * 1994-12-30 1996-07-11 Chiron Viagene, Inc. Direct administration of gene delivery vehicles at multiple sites
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
US6630455B1 (en) 1995-01-13 2003-10-07 Vanderbilt University Methods for inducing mucosal immune responses
CA2188575A1 (en) 1995-02-28 1996-09-06 H. Kirk Hammond Gene transfer-mediated angiogenesis therapy
US20030148968A1 (en) * 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
US6176842B1 (en) 1995-03-08 2001-01-23 Ekos Corporation Ultrasound assembly for use with light activated drugs
US6210356B1 (en) 1998-08-05 2001-04-03 Ekos Corporation Ultrasound assembly for use with a catheter
US6531455B1 (en) 1995-03-24 2003-03-11 The Regents Of The University Of California Delivery of polynucleotides by secretory gland expression
US5885971A (en) * 1995-03-24 1999-03-23 The Regents Of The University Of California Gene therapy by secretory gland expression
US5837693A (en) * 1995-03-24 1998-11-17 The Regents Of The University Of California Intravenous hormone polypeptide delivery by salivary gland expression
US5922687A (en) * 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US5766901A (en) * 1995-05-04 1998-06-16 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and method for delivering a nucleotide into cell nuclei
US6322548B1 (en) 1995-05-10 2001-11-27 Eclipse Surgical Technologies Delivery catheter system for heart chamber
US6638264B1 (en) * 1995-05-16 2003-10-28 Biostratum Incorporation Perfusion apparatus and methods for pharmaceutical delivery
EP0831919B1 (de) * 1995-05-16 2002-10-16 TRYGGVASON, Karl Verfahren zur arzneistoffabgabe mittels gentherapie
US5797870A (en) * 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
US5674198A (en) * 1995-06-23 1997-10-07 Cordis Corporation Tandem balloon catheter
AU708273B2 (en) * 1995-06-27 1999-07-29 Bavarian Nordic A/S Encapsulated cells producing viral particles
US6254862B1 (en) 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US7011976B1 (en) 1997-03-03 2006-03-14 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US5725568A (en) * 1995-06-27 1998-03-10 Scimed Life Systems, Inc. Method and device for recanalizing and grafting arteries
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US5837534A (en) * 1995-11-14 1998-11-17 The Board Of Regents Of The University Of Texas System Smooth muscle 22α promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells
PL186018B1 (pl) * 1995-11-30 2003-09-30 Regents Board Of Sposoby i kompozycje do diagnozowania i leczenia nowotworu
EP0871512A1 (de) * 1995-12-22 1998-10-21 Localmed, Inc. Lokale intravaskuläre abgabe von wachsfaktoren zur stimulierung von angiogenese
US5998384A (en) * 1996-01-26 1999-12-07 Hisamitsu Pharmaceutical Co., Inc. Endoscopic administration of an HSV-tk gene to treat digestive organ cancer
WO1997028817A1 (en) * 1996-02-09 1997-08-14 Cheng Pi Wan Receptor ligand-facilitated delivery of biologically active molecules
AU721034B2 (en) 1996-02-15 2000-06-22 Biosense, Inc. Catheter based surgery
US6037332A (en) * 1996-02-20 2000-03-14 Emory University Method of urinary bladder instillation
US5866340A (en) * 1996-03-22 1999-02-02 Johns Hopkins University Selective expression of desired genes in cells expressing oncoproteins
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
DE19620687A1 (de) * 1996-05-22 1997-11-27 Centeon Pharma Gmbh Neuer adenoviraler Vektor für den Transfer humaner Gene in vivo
WO1998002040A1 (en) 1996-07-17 1998-01-22 Medtronic, Inc. System for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment
WO1998002150A1 (en) * 1996-07-17 1998-01-22 Medtronic, Inc. System for genetically treating cardiac conduction disturbances
US6443974B1 (en) 1996-07-28 2002-09-03 Biosense, Inc. Electromagnetic cardiac biostimulation
US6225290B1 (en) * 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
US6335010B1 (en) * 1996-11-08 2002-01-01 University Of California At San Diego Gene therapy in coronary angioplasty and bypass
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5868719A (en) * 1997-01-15 1999-02-09 Boston Scientific Corporation Drug delivery balloon catheter device
US6494861B1 (en) 1997-01-15 2002-12-17 Boston Scientific Corporation Drug delivery system
KR20000070731A (ko) * 1997-02-04 2000-11-25 찰스 더블유 프란즈 치골 상부 배출 카테터
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US5837283A (en) 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
WO1998044938A1 (en) * 1997-04-10 1998-10-15 University Of Southern California Modified proteins which bind extracellular matrix components
DK0975755T3 (da) 1997-04-16 2007-06-11 Millennium Pharm Inc CRSP-protein (cysteinrige udskilte proteiner), nukleinsyremolekyler der koder herfor samt anvendelser deraf
US6723063B1 (en) * 1998-06-29 2004-04-20 Ekos Corporation Sheath for use with an ultrasound element
US6582392B1 (en) 1998-05-01 2003-06-24 Ekos Corporation Ultrasound assembly for use with a catheter
US6676626B1 (en) * 1998-05-01 2004-01-13 Ekos Corporation Ultrasound assembly with increased efficacy
WO1998048711A1 (en) * 1997-05-01 1998-11-05 Ekos Corporation Ultrasound catheter
DE19726244C2 (de) * 1997-06-20 2000-03-02 Mucos Pharma Gmbh & Co Verwendung proteolytischer Enzyme und Rutosid zur Vorbeugung bzw. Behandlung der Transplantatabstoßung
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6994851B1 (en) * 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
DE19729769A1 (de) 1997-07-11 1999-01-14 Cardiogene Gentherapeutische S Transfektionssystem, seine Herstellung und Verwendung in der somatischen Gentherapie
US6177272B1 (en) * 1997-07-21 2001-01-23 The Regents Of The University Of Michigan Method for treating vascular proliferative diseases with p27 and fusions thereof
US20090239940A1 (en) * 1997-07-22 2009-09-24 Del Monte Federica Treating heart failure and ventricular arrhythmias
WO1999006576A1 (en) 1997-08-04 1999-02-11 Calydon, Inc. A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
AU9692198A (en) 1997-10-10 1999-05-03 Kevin J. Donahue Gene delivery compositions and methods
US20020055731A1 (en) * 1997-10-24 2002-05-09 Anthony Atala Methods for promoting cell transfection in vivo
US6610497B1 (en) * 1997-12-11 2003-08-26 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6197324B1 (en) 1997-12-18 2001-03-06 C. R. Bard, Inc. System and methods for local delivery of an agent
US6251418B1 (en) * 1997-12-18 2001-06-26 C.R. Bard, Inc. Systems and methods for local delivery of an agent
US6699231B1 (en) 1997-12-31 2004-03-02 Heartport, Inc. Methods and apparatus for perfusion of isolated tissue structure
US6794369B2 (en) 1997-12-31 2004-09-21 Pharmasonics Methods, systems, and kits for intravascular nucleic acid delivery
JP2001526942A (ja) 1997-12-31 2001-12-25 ファーマソニックス，インコーポレイテッド 血管内核酸送達のための方法、システム、およびキット
US6221425B1 (en) 1998-01-30 2001-04-24 Advanced Cardiovascular Systems, Inc. Lubricious hydrophilic coating for an intracorporeal medical device
US20030113303A1 (en) * 1998-02-05 2003-06-19 Yitzhack Schwartz Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances
ES2255155T3 (es) 1998-02-05 2006-06-16 Biosense Webster, Inc. Dispositivo para la administracion intracardiaca de farmacos.
US20030129750A1 (en) * 1998-02-05 2003-07-10 Yitzhack Schwartz Homing of donor cells to a target zone in tissue using active therapeutics or substances
US7749215B1 (en) * 1998-02-05 2010-07-06 Biosense, Inc. Intracardiac cell delivery and cell transplantation
AU767662B2 (en) 1998-02-06 2003-11-20 Collateral Therapeutics, Inc. Variants of the angiogenic factor vascular endothelial cell growth factor: VEGF
US6148222A (en) * 1998-07-10 2000-11-14 Cardiocommand, Inc. Esophageal catheters and method of use
US7700353B2 (en) * 1998-07-22 2010-04-20 E-P Therapeutics, Inc. Compositions and methods for inducing apoptosis in tumor cells
DE69935862T2 (de) * 1998-08-26 2008-01-10 Stürzl, Michael, Prof. Dr. rer. nat. Guanylat-bindendes protein (gbp-1) als inhibitor der zellproliferation
US6312402B1 (en) 1998-09-24 2001-11-06 Ekos Corporation Ultrasound catheter for improving blood flow to the heart
US6689121B1 (en) 1998-09-24 2004-02-10 C. R. Bard, Inc. Systems and methods for treating ischemia
US6135976A (en) * 1998-09-25 2000-10-24 Ekos Corporation Method, device and kit for performing gene therapy
US6251079B1 (en) 1998-09-30 2001-06-26 C. R. Bard, Inc. Transthoracic drug delivery device
US20030027998A1 (en) * 1998-10-30 2003-02-06 Holtzman Douglas A. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
US20060205034A1 (en) * 1998-10-30 2006-09-14 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
EP1129064B1 (de) 1998-11-12 2008-01-09 Invitrogen Corporation Transportreagentien
ATE267032T1 (de) * 1998-12-14 2004-06-15 Tre Esse Progettazione Biomedi Kathetersystem zur durchführung einer intramyokardialen therapeutischen behandlung
US7481803B2 (en) * 2000-11-28 2009-01-27 Flowmedica, Inc. Intra-aortic renal drug delivery catheter
US7122019B1 (en) 2000-11-28 2006-10-17 Flowmedica Inc. Intra-aortic renal drug delivery catheter
US7780628B1 (en) 1999-01-11 2010-08-24 Angiodynamics, Inc. Apparatus and methods for treating congestive heart disease
US7329236B2 (en) * 1999-01-11 2008-02-12 Flowmedica, Inc. Intra-aortic renal drug delivery catheter
US6749598B1 (en) * 1999-01-11 2004-06-15 Flowmedica, Inc. Apparatus and methods for treating congestive heart disease
US6695830B2 (en) * 1999-01-15 2004-02-24 Scimed Life Systems, Inc. Method for delivering medication into an arterial wall for prevention of restenosis
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
WO2000050443A2 (en) 1999-02-26 2000-08-31 Millennium Pharmaceutcals, Inc. Secreted proteins and uses thereof
JP2002538167A (ja) 1999-03-03 2002-11-12 バイオジェン インコーポレイテッド 脂質の代謝および貯蔵を調節する方法
EP1165132B1 (de) * 1999-04-08 2011-10-19 Intercell USA, Inc. Trockenformulierung für transkutane immunisierung
US6224566B1 (en) 1999-05-04 2001-05-01 Cardiodyne, Inc. Method and devices for creating a trap for confining therapeutic drugs and/or genes in the myocardium
US6565528B1 (en) 1999-05-07 2003-05-20 Scimed Life Systems, Inc. Apparatus and method for delivering therapeutic and diagnostic agents
US20040229779A1 (en) * 1999-05-14 2004-11-18 Ramesh Kekuda Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6974684B2 (en) * 2001-08-08 2005-12-13 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040023874A1 (en) * 2002-03-15 2004-02-05 Burgess Catherine E. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6774120B1 (en) * 1999-06-01 2004-08-10 Sarah Ferber Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
US8778899B2 (en) 1999-06-01 2014-07-15 Sarah Ferber Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
AU5595300A (en) 1999-06-02 2000-12-18 Microheart, Inc. Devices and methods for delivering a drug
US7147633B2 (en) * 1999-06-02 2006-12-12 Boston Scientific Scimed, Inc. Method and apparatus for treatment of atrial fibrillation
US20040067490A1 (en) * 2001-09-07 2004-04-08 Mei Zhong Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7001766B2 (en) * 1999-07-20 2006-02-21 Curagen Corporation Nucleic acid sequences encoding human angiopoietin-like polypeptides
US6475744B1 (en) 1999-07-22 2002-11-05 The General Hospital Corporation Methods for identifying compounds which modulate circadian rhythm
WO2001006989A2 (en) * 1999-07-27 2001-02-01 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
US6855160B1 (en) 1999-08-04 2005-02-15 C. R. Bard, Inc. Implant and agent delivery device
JP4896327B2 (ja) 1999-08-23 2012-03-14 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド Ｐｄ−１、ｂ７−４の受容体、およびその使用
US6429303B1 (en) 1999-09-03 2002-08-06 Curagen Corporation Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same
AU782714B2 (en) * 1999-09-09 2005-08-25 Regents Of The University Of California, The Cationic liposome delivery of taxanes to angiogenic blood vessels
AU7612100A (en) * 1999-09-24 2001-04-24 Johns Hopkins University, The Systems and methods for opening obstructed biological conduits
US6855806B1 (en) * 1999-10-15 2005-02-15 Curagen Corporation Thymosin beta 10-like proteins and nucleic acids encoding same
US6759520B1 (en) 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US8808272B2 (en) * 1999-10-28 2014-08-19 Boston Scientific Scimed, Inc. Biocompatible medical devices
DE10100586C1 (de) * 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
US8168178B2 (en) * 1999-11-30 2012-05-01 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US6951839B1 (en) 1999-11-30 2005-10-04 Curis, Inc. Methods and compositions for regulating lymphocyte activity
CA2401775A1 (en) 2000-02-29 2001-09-07 Abbot F. Clark Diagnostics and therapeutics for glaucoma
EP1254230A2 (de) 2000-02-29 2002-11-06 Millennium Pharmaceuticals, Inc. 1983, 52881, 2398, 45449, 50289, and 52872, g-protein-gekoppelte rezeptoren und deren anwendungen
ATE348161T1 (de) * 2000-03-03 2007-01-15 Curagen Corp Fctrx genannte proteine und dafür kodierende nuklein säure
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7517352B2 (en) 2000-04-07 2009-04-14 Bacchus Vascular, Inc. Devices for percutaneous remote endarterectomy
AU2001259063A1 (en) 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
EP2336169A1 (de) 2000-04-21 2011-06-22 New England Medical Center Hospital G-Protein gekoppelte Rezeptor (GPCR)-Agonisten und -Antagonisten sowie Verfahren zur GPCR-Aktivierung/ -Inhibierung.
WO2001084149A2 (en) 2000-04-29 2001-11-08 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US20040005554A1 (en) * 2000-05-08 2004-01-08 Tayar Nabil El Novel glycoproteins and methods of use thereof
US20030219786A1 (en) * 2000-08-11 2003-11-27 Applied Research Systems Ars Holding N.V. Novel glycoproteins and methods of use thereof
US7232421B1 (en) 2000-05-12 2007-06-19 C. R. Bard, Inc. Agent delivery systems
EP1714661A3 (de) 2000-05-19 2012-03-14 The Center for Blood Research, INC. Verfahren zur Diagnose und Behandlung von hämostatischen Störungen durch Modulation der P-Selectin Aktivität
US20050048614A1 (en) * 2000-06-13 2005-03-03 Children's Medical Center Corporation Biosynthetic oncolytic molecules and uses therefor
US20040034193A1 (en) * 2001-06-13 2004-02-19 Samy Ashkar Biosynthetic oncolytic molecules and uses therefor
US20040023259A1 (en) * 2000-07-26 2004-02-05 Luca Rastelli Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CA2417982A1 (en) * 2000-08-03 2002-02-14 The University Of Utah Research Foundation Manipulation of arterial-venous identity
WO2002016644A1 (en) * 2000-08-18 2002-02-28 Massachusetts Institute Of Technology Inhibition of protein-protein interaction
US6740331B1 (en) 2000-08-25 2004-05-25 Global Gene Therapies, Inc. Apparatus for the delivery of drugs or gene therapy into a patient's vasculature and methods of use
US7651696B2 (en) * 2000-08-25 2010-01-26 Nexeon Medical Systems, Inc. Implantable device for treating disease states and methods of using same
DE60140457D1 (de) 2000-09-01 2009-12-24 Blood Res Center Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
ATE532860T1 (de) * 2000-09-20 2011-11-15 Amgen Inc B7-ähnliche moleküle und deren anwendungen
EP1421174B1 (de) 2000-10-18 2009-12-23 The Brigham And Women's Hospital, Inc. E-selectin/l-selectin-liganden-polypeptide hämatopoetischer zellen und verfahren zu deren verwendung
JP2004526425A (ja) 2000-11-28 2004-09-02 ワイス 前立腺癌の診断および治療に有用なｆｋｂｐ核酸およびポリペプチドの発現分析
EP1343912A2 (de) 2000-11-28 2003-09-17 Wyeth Expressionsanalyse von kiaa nukleinsäuren und polypeptiden, geeignet zur diagnose und zur behandlung von prostatakrebs
AU2002236517A1 (en) * 2000-11-29 2002-06-11 University Of Southern California Targetet retoviral vectors for cancer immunotherapy
US7247704B2 (en) 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
US7767802B2 (en) * 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7423142B2 (en) * 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US6964849B2 (en) 2001-01-11 2005-11-15 Curagen Corporation Proteins and nucleic acids encoding same
US20040043928A1 (en) * 2001-08-02 2004-03-04 Ramesh Kekuda Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002064618A2 (en) * 2001-02-09 2002-08-22 Massachusetts Institute Of Technology Methods of identifying agents that mediate polypeptide aggregation
CA2437899C (en) 2001-02-13 2012-05-15 Gregory M. Glenn Vaccine for transcutaneous immunization against etec-caused traveler's diarrhea
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US20090081199A1 (en) * 2001-03-20 2009-03-26 Bioxell S.P.A. Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
CA2342376C (en) * 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) * 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
EP2388590A1 (de) 2001-04-02 2011-11-23 Dana Farber Cancer Institute PD-1, ein Rezeptor für B7-4, und Verwendungen dafür
US20030148298A1 (en) * 2001-04-03 2003-08-07 O''toole Margot Methods for diagnosing and treating systemic lupus erythematosus disease and compositions thereof
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
EP2261241A1 (de) 2001-04-16 2010-12-15 Wyeth Holdings Corporation Polypeptidantigene codierende offene leseraster aus streptococcus pneumoniae und verwendungen davon
US20030017159A1 (en) * 2001-05-02 2003-01-23 Jerome Ritz Immunogenic tumor antigens: nucleic acids and polypeptides encoding the same and methods of use thereof
US7244853B2 (en) * 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
BR0210283A (pt) * 2001-06-07 2004-09-14 Wyeth Corp Receptor acoplado à proteìna-g e usos para o mesmo
CA2449628C (en) 2001-06-07 2008-05-06 Zheng Wei Cell migration assay
CA2450809A1 (en) * 2001-06-15 2002-12-27 Interleukin Genetics, Inc. Methods for detecting and treating the early onset of aging-related conditions
US20040236377A1 (en) * 2001-07-02 2004-11-25 Medtronic, Inc. System and method for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment
US20040029790A1 (en) * 2001-07-05 2004-02-12 Meera Patturajan Novel human proteins, polynucleotides encoding them and methods of using the same
US20030129613A1 (en) * 2001-07-05 2003-07-10 Fernandes Elma R. Novel human proteins and polynucleotides encoding them
US20030087274A1 (en) * 2001-07-05 2003-05-08 Anderson David W. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP2360251B1 (de) 2001-07-12 2016-09-28 University of Massachusetts In-vivo-Herstellung kleiner interferierender und Genverstummung vermittelnder RNAs
EP1900815B1 (de) 2001-07-12 2016-09-07 University of Massachusetts In-vivo-Herstellung kleiner interferierender und Genverstummung vermittelnder RNAs
US20040030096A1 (en) * 2001-08-02 2004-02-12 Linda Gorman Novel human proteins, polynucleotides encoding them and methods of using the same
WO2003015615A2 (en) 2001-08-15 2003-02-27 Brown University Research Foundation Treatment of muscular dystrophies and related disorders
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US7981863B2 (en) 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
DE60238872D1 (de) 2001-09-28 2011-02-17 Univ Brigham Young Neue cyclooxygenase-varianten und verwendungsverfahren
US6808518B2 (en) 2001-09-28 2004-10-26 Ethicon, Inc. Methods and devices for treating diseased blood vessels
IL161137A0 (en) * 2001-10-01 2004-08-31 Bradley H Strauss Use of a formulation containing collagenase for degrading collagen in occluded arteries
US20030096260A1 (en) * 2001-10-09 2003-05-22 Zhenhua Miao Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
US20030215460A1 (en) * 2002-05-07 2003-11-20 Schall Thomas J. Methods and compositions for inducing an immune response
US20030199442A1 (en) * 2001-10-09 2003-10-23 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7745418B2 (en) * 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
ATE333923T1 (de) * 2001-12-03 2006-08-15 Ekos Corp Ultraschallkatheter für kleine gefässe
ATE319378T1 (de) 2001-12-03 2006-03-15 Ekos Corp Katheter mit mehreren ultraschall-abstrahlenden teilen
US7141044B2 (en) 2001-12-11 2006-11-28 Ekos Corporation Alternate site gene therapy
WO2003053363A2 (en) 2001-12-19 2003-07-03 Millennium Pharmaceuticals, Inc. Human diacylglycerol acyltransferase 2 (dgat2) family members and uses therefor
US6939374B2 (en) * 2001-12-21 2005-09-06 Scimed Life Systems, Inc. Stents, stenting systems, and related methods for agent delivery
EP1463751B1 (de) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albuminfusionsproteine
EP1471928A1 (de) 2002-02-07 2004-11-03 Delta Biotechnology Limited Hiv hemmende proteine
AU2003212481A1 (en) * 2002-02-28 2003-09-09 Ekos Corporation Ultrasound assembly for use with a catheter
US7153685B2 (en) * 2002-03-11 2006-12-26 The Board Of Trustees Of The University Of Illinois Tamoxifen and 4-hydroxytamoxifen-activated system for regulated production of proteins in eukaryotic cells
US8226629B1 (en) 2002-04-01 2012-07-24 Ekos Corporation Ultrasonic catheter power control
AU2003233008B2 (en) * 2002-04-22 2008-04-24 Recopharma Ab Fusion polypeptides and methods for inhibiting microbial adhesion
EP2392659B1 (de) 2002-06-17 2015-01-14 Thrasos Innovation, Inc. TDF-zugehörige Einzeldomänenverbindungen und Analoge davon
CN1688340A (zh) * 2002-07-15 2005-10-26 韦思公司 调节t辅助(th)细胞发育和功能的方法和组合物
EP2311978A1 (de) 2002-08-20 2011-04-20 Millennium Pharmaceuticals, Inc. Zusammensetzungen, Kits und Verfahren zur Identifizierung, Beurteilung, Vorbeugung und Therapie von Gebärmutterhalskrebs
EP1624909A2 (de) * 2002-09-20 2006-02-15 FlowMedica, Inc. Gerät und verfahren zur einführung eines intraaortakalen katheters durch eine ablageschleuse
US20050197624A1 (en) 2004-03-04 2005-09-08 Flowmedica, Inc. Sheath for use in peripheral interventions
AU2003294226A1 (en) * 2002-09-20 2004-04-23 Flowmedica, Inc. Method and apparatus for intra aortic substance delivery to a branch vessel
US7993325B2 (en) 2002-09-20 2011-08-09 Angio Dynamics, Inc. Renal infusion systems and methods
EP1539291A4 (de) 2002-09-20 2010-03-10 Flowmedica Inc Verfahren und gerät für die selektive materialabgabe über einen intrarenalen katheter
US7063679B2 (en) * 2002-09-20 2006-06-20 Flowmedica, Inc. Intra-aortic renal delivery catheter
US6921371B2 (en) 2002-10-14 2005-07-26 Ekos Corporation Ultrasound radiating members for catheter
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
AU2003298650B2 (en) * 2002-11-15 2010-03-11 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
US20050037011A1 (en) * 2002-11-21 2005-02-17 Jones Stephen N. Diagnosing and treating hematopoietic cancers
EP2112229A3 (de) 2002-11-25 2009-12-02 Sequenom, Inc. Verfahren zum Identifizieren des Brustkrebsrisikos und zugehörige Behandlungen
US7771372B2 (en) 2003-01-03 2010-08-10 Ekos Corporation Ultrasonic catheter with axial energy field
AU2004213050B2 (en) * 2003-02-20 2010-09-09 Proteon Therapeutics, Inc. Methods for the treatment and prevention of diseases of biological conduits
US20050233342A1 (en) * 2003-03-07 2005-10-20 Muthiah Manoharan Methods of preventing off-target gene silencing
US20070179100A1 (en) * 2003-04-09 2007-08-02 Muthiah Manoharan Protected monomers
US8017762B2 (en) * 2003-04-17 2011-09-13 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
US7851615B2 (en) * 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
US8796436B2 (en) 2003-04-17 2014-08-05 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
CA2522349A1 (en) 2003-04-17 2004-11-04 Alnylam Pharmaceuticals, Inc. Protected monomers
US7723509B2 (en) 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
EP2669377A3 (de) 2003-04-17 2015-10-14 Alnylam Pharmaceuticals Inc. Modifizierte iRNA-Wirkstoffe
US20090123428A1 (en) * 2003-04-21 2009-05-14 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US8052966B2 (en) * 2003-04-21 2011-11-08 University Of Southern California Methods and compositions for treating metastatic cancer
EP1619995A2 (de) 2003-04-22 2006-02-01 Ekos Corporation Ultraschallverstärkter zentralvenöser katheter
JP2006526464A (ja) 2003-06-05 2006-11-24 フローメディカ，インコーポレイテッド 分枝した身体管腔において両側介入または診断を行うためのシステムおよび方法
EP1635763B1 (de) 2003-06-09 2012-08-08 Alnylam Pharmaceuticals Inc. Verfahren zur behandlung von neurodegenerativen erkrankungen
US7595306B2 (en) * 2003-06-09 2009-09-29 Alnylam Pharmaceuticals Inc Method of treating neurodegenerative disease
US20060134287A1 (en) * 2003-08-20 2006-06-22 Vimini Robert J Packaging and cooking bag and method for packaging and preparing a meat product
ES2366830T3 (es) * 2003-08-25 2011-10-25 Funzyme Biotechnologies Sa Nuevas proteínas fúngicas y ácidos nucelicos que codifican las mismas.
WO2005023292A1 (en) 2003-09-03 2005-03-17 The General Hospital Corporation Methods of treating restenosis
US8680063B2 (en) 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
EP1670518B1 (de) * 2003-09-12 2014-05-21 University of Massachusetts Rna-interferenz zur behandlung von funktionszunahmestörungen
US20050059999A1 (en) * 2003-09-15 2005-03-17 Mongeon Luc R. Delivering genetic material to a stimulation site
EP2051077A3 (de) 2003-10-07 2009-05-27 Millennium Pharmaceuticals, Inc. Nucleinsäuremoleküle und Proteine zur Identifizierung, Beurteilung, Vorbeugung und Therapie von Eierstockkrebs
US7576052B2 (en) 2003-10-17 2009-08-18 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
US20050125914A1 (en) * 2003-11-18 2005-06-16 Gerard Malle Hair shaping composition comprising at least one- non-hydroxide base
WO2005051206A1 (en) 2003-11-21 2005-06-09 Vnus Medical Technologies, Inc. Method and apparatus for treating a carotid artery
CA2487107A1 (en) * 2003-12-22 2005-06-22 F. Hoffmann-La Roche Ag Novel targets for obesity from skeletal muscle
CA2487098A1 (en) * 2003-12-22 2005-06-22 F. Hoffmann-La Roche Ag Novel targets for obesity from fat tissue
US20070087986A1 (en) * 2004-01-26 2007-04-19 Brett Premack Compositions and methods for enhancing immunity by chemoattractant adjuvants
EP1711206A2 (de) * 2004-01-26 2006-10-18 ChemoCentryx Inc Zusammensetzungen und verfahren zur verwendung von w-peptiden
EP2816351A3 (de) * 2004-01-27 2015-03-25 Compugen Ltd. Verfahren und Systeme zur Annotation biomolekularer Sequenzen
EP1716227A4 (de) * 2004-01-27 2010-01-06 Compugen Ltd Verfahren zur identifizierung putativer genprodukte mittels interspezies-sequenzvergleich sowie damit entdeckte biomolekulare sequenzen
US8404747B2 (en) * 2004-03-05 2013-03-26 The General Hospital Corporation Compositions and methods for modulating interaction between polypeptides
AU2005222902B2 (en) * 2004-03-12 2010-06-10 Alnylam Pharmaceuticals, Inc. iRNA agents targeting VEGF
GB0406728D0 (en) * 2004-03-25 2004-04-28 Hydrodynamic Gene Delivery Ltd Gene therapy
CA2561714A1 (en) * 2004-04-08 2005-10-27 Sangamo Biosciences, Inc. Methods and compositions for treating neuropathic and neurodegenerative conditions
ES2527528T3 (es) * 2004-04-08 2015-01-26 Sangamo Biosciences, Inc. Métodos y composiciones para modular la contractilidad cardiaca
JP2007537298A (ja) 2004-05-14 2007-12-20 フロウメディカ， インコーポレイテッド うっ血性心不全の処置およびｂｎｐ療法のための両側性局所腎臓送達
AU2005250369A1 (en) * 2004-05-18 2005-12-15 Genentech, Inc. M13 virus major coat protein variants for C-terminal and BI-terminal display of a heterologous protein
EP1753458A4 (de) * 2004-05-19 2009-07-22 Wyeth Corp Modulation der immunglobulinproduktion und atopische erkrankungen
WO2006007377A2 (en) * 2004-06-16 2006-01-19 The General Hospital Corporation Methods of screening for bridge-1-mediated disorders, including type ii diabetes
EP1773871B1 (de) 2004-06-17 2014-10-15 Thrasos Innovation, Inc. Mit tdf verwandte verbindungen und analoga davon
US7342093B2 (en) 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
US20060051338A1 (en) 2004-08-20 2006-03-09 New York University Inhibition of mitogen-activated protein kinases in cardiovascular disease
CA2579349A1 (en) 2004-09-07 2006-03-16 Telethon Institute For Child Health Research Agents for treatment or prevention of an allergic disorder
US20060069323A1 (en) * 2004-09-24 2006-03-30 Flowmedica, Inc. Systems and methods for bi-lateral guidewire cannulation of branched body lumens
AU2005289588B2 (en) 2004-09-24 2011-12-22 Alnylam Pharmaceuticals, Inc. RNAi modulation of ApoB and uses thereof
EP1814597A4 (de) 2004-11-24 2009-04-22 Alnylam Pharmaceuticals Inc Rnai-modulation des bcr-abl-fusionsgens und dessen verwendungen
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
JP2008521575A (ja) * 2004-12-01 2008-06-26 ジェンザイム・コーポレイション 肝臓を標的とした遺伝物質の送達方法
US20060154285A1 (en) * 2004-12-29 2006-07-13 Robishaw Janet D Zebrafish heterotrimer G-protein gamma 2 subunit (GNG2)
AU2006208084B2 (en) 2005-01-25 2012-07-26 Prolexys Pharmaceuticals, Inc. Quinoxaline Derivatives as Antitumor Agents
JP5058822B2 (ja) 2005-01-25 2012-10-24 ファイブ プライム セラピューティクス， インコーポレイテッド 心臓の状態を処置するための組成物および方法
CA2937005A1 (en) 2005-03-22 2006-09-28 President And Fellows Of Harvard College Treatment of protein degradation disorders
MX2007014474A (es) 2005-05-17 2008-02-07 Univ Connecticut Composiciones y metodos para inmunomodulacion en un organismo.
WO2006135783A2 (en) * 2005-06-10 2006-12-21 Wisconsin Alumni Research Foundation Compositions and methods for modulating angiogenesis
JP2008543449A (ja) * 2005-06-17 2008-12-04 アボット・ラボラトリーズ 変性脊椎疾患の改良型治療方法
ES2710601T3 (es) 2005-07-19 2019-04-26 Stemgen S P A Inhibición del potencial tumorigénico de células madre tumorales por LIF
JP2009502138A (ja) * 2005-07-21 2009-01-29 アルナイラム ファーマシューティカルズ インコーポレイテッド ＲｈｏＡ遺伝子のＲＮＡｉ調節及びその使用法
WO2007018318A1 (ja) * 2005-08-10 2007-02-15 National University Corporation Kanazawa University 小脳星状細胞及び／又は籠細胞特異的な遺伝子発現方法
EP1937066A4 (de) * 2005-08-18 2008-12-24 Alnylam Pharmaceuticals Inc Verfahren und zusammensetzungen für die behandlung von nervenkrankheiten
WO2007024589A2 (en) * 2005-08-24 2007-03-01 The Trustees Of Columbia University In The City Of New York Phagocyte enhancement therapy for atherosclerosis
TWI333959B (en) * 2005-08-31 2010-12-01 Academia Sinica Methods and reagents for the analysis and purification of polysaccharides
US7943134B2 (en) 2005-08-31 2011-05-17 Academia Sinica Compositions and methods for identifying response targets and treating flavivirus infection responses
WO2007030820A2 (en) 2005-09-09 2007-03-15 The Johns Hopkins University Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists
EP2497780B1 (de) 2005-09-20 2015-04-15 Thrasos Innovation, Inc. Verbindungen im Zusammenhang mit TDF und Analoga davon
CA2624662A1 (en) 2005-09-30 2007-04-12 The Government Of The United States Of America, As Represented By The Se Cretary Of Health And Human Services Methods and compositions for modulating immune tolerance
US20070100323A1 (en) * 2005-10-31 2007-05-03 Ludwig Florian N Facilitation of endothelialization by in situ surface modification
KR20080086440A (ko) * 2005-11-01 2008-09-25 알닐람 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 ＲＮＡｉ 억제
EP1942948A4 (de) * 2005-11-04 2010-03-03 Alnylam Pharmaceuticals Inc Zusammensetzungen und verfahren zur hemmung der expression des nav1.8-genes
US20070105835A1 (en) * 2005-11-07 2007-05-10 Kazantsev Aleksey G Compositions and methods for modulating poly(ADP-ribose) polymerase activity
EP1945270B1 (de) 2005-11-09 2011-05-25 Alnylam Pharmaceuticals Inc. Zusammensetzungen und verfahren zur hemmung der expression von faktor v leiden mutationsgen
DE602005023550D1 (de) 2005-12-14 2010-10-21 Licentia Ltd Verwendungen eines neurotrophischen Faktors
US8172792B2 (en) * 2005-12-27 2012-05-08 Tyco Healthcare Group Lp Embolic protection systems for bifurcated conduits
AU2007251256B2 (en) 2006-01-26 2013-03-07 Recopharma Ab Compositions and methods for inhibiting viral adhesion
US8229398B2 (en) * 2006-01-30 2012-07-24 Qualcomm Incorporated GSM authentication in a CDMA network
EP1818395A1 (de) 2006-02-08 2007-08-15 Diatos Zusammensetzungen und Verfahren zur Behandlung der Lysosomen-Speichererkrankungen
CN101437833A (zh) 2006-02-10 2009-05-20 辛辛那提大学 作为心脏功能调节剂的磷酸酶抑制剂蛋白-1
AU2007345292B2 (en) * 2006-02-14 2013-10-31 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
US20090221072A1 (en) * 2006-02-15 2009-09-03 Chen Thomas T Compositions and methods for modulating cell differentiation
US20070225750A1 (en) * 2006-03-10 2007-09-27 Brooke Ren Embolic protection systems
KR101547579B1 (ko) 2006-03-31 2015-08-27 알닐람 파마슈티칼스 인코포레이티드 Ｅｇ5 유전자의 발현을 억제하는 이본쇄 리보핵산
US7695928B2 (en) 2006-04-10 2010-04-13 Genentech, Inc. Disheveled PDZ modulators
US7691824B2 (en) * 2006-04-28 2010-04-06 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a gene from the JC virus
US8304451B2 (en) * 2006-05-03 2012-11-06 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
US20090304704A1 (en) 2006-05-03 2009-12-10 Geisinger Clinic Methods for diagnosing and predicting non-alcoholic steatohepatitis (nash)
NZ587616A (en) 2006-05-11 2012-03-30 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of the pcsk9 gene
ATE528008T1 (de) * 2006-05-19 2011-10-15 Alnylam Pharmaceuticals Inc Rnai-modulation von aha und ihre therapeutische verwendung
EP2192200B1 (de) 2006-05-22 2012-10-24 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und Verfahren zur Hemmung der IKK-B-Gen-Expression
US8383597B2 (en) * 2006-05-25 2013-02-26 Cornell Research Foundation, Inc. G proteins in tumor growth and angiogenesis
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
CA2654165A1 (en) 2006-06-05 2007-12-13 Cancer Care Ontario Assessment of risk for colorectal cancer
US7771401B2 (en) 2006-06-08 2010-08-10 Angiodynamics, Inc. Selective renal cannulation and infusion systems and methods
ES2523640T3 (es) 2006-06-21 2014-11-28 Musc Foundation For Research Development Direccionamiento del factor H del complemento para el tratamiento de enfermedades
WO2008054561A2 (en) 2006-07-11 2008-05-08 University Of Medicine And Dentistry Of New Jersey Proteins, nucleic acids encoding the same and associated methods of use
US20080021063A1 (en) * 2006-07-18 2008-01-24 Kazantsev Aleksey G Compositions and methods for modulating sirtuin activity
US8153803B2 (en) * 2006-07-18 2012-04-10 The General Hospital Corporation Compositions and methods for modulating sirtuin activity
US7943310B2 (en) * 2006-08-30 2011-05-17 Centocor Ortho Biotech Inc. Methods for assessing response to therapy in subjects having ulcerative colitis
EP2418291A1 (de) 2006-09-14 2012-02-15 Institut Pasteur Ein CD26 (DPP-4) inhibitor in der Verwendung zur Behandlung einer HCV-Infektion
KR101161923B1 (ko) 2006-10-03 2012-07-03 유니버시티 오브 메디신 앤드 덴티스트리 오브 뉴 저지 Ａｔａｐ 펩티드, 상기 펩티드를 엔코딩하는 핵산 및 이들과 관련된 사용 방법
US8192363B2 (en) 2006-10-27 2012-06-05 Ekos Corporation Catheter with multiple ultrasound radiating members
DE102006051623A1 (de) 2006-11-02 2008-07-31 Horn, Peter A. Verfahren und Stoffgemisch zur Verbesserung eines in vivo Genfransfers
ES2777652T3 (es) 2006-12-21 2020-08-05 H Lundbeck As Modulación de la actividad de proneurotrofinas
US10182833B2 (en) 2007-01-08 2019-01-22 Ekos Corporation Power parameters for ultrasonic catheter
EP2423220B1 (de) 2007-01-30 2015-04-29 Epivax, Inc. Regulatorische t-zellen-epitope sowie zusammensetzungen damit und anwendungen davon
WO2008103336A1 (en) * 2007-02-21 2008-08-28 Cook Incorporated Methods for intravascular engraftment in heart
WO2008106785A1 (en) 2007-03-05 2008-09-12 Cancer Care Ontario Assessment of risk for colorectal cancer
EP2134365B1 (de) 2007-03-21 2019-03-13 Effat Emamian Zusammensetzung und verfahren zur hemmung von zellwachstum
PE20090064A1 (es) 2007-03-26 2009-03-02 Novartis Ag Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
WO2008143774A2 (en) * 2007-05-01 2008-11-27 University Of Massachusetts Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
AR066984A1 (es) * 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
PL2170181T3 (pl) 2007-06-22 2014-08-29 Ekos Corp Sposób i aparat do leczenia wylewów wewnątrzczaszkowych
WO2009004085A2 (en) 2007-07-05 2009-01-08 Novartis Ag Dsrna for treating viral infection
US8858490B2 (en) 2007-07-18 2014-10-14 Silk Road Medical, Inc. Systems and methods for treating a carotid artery
EP2173425B1 (de) 2007-07-18 2012-11-21 Silk Road Medical, Inc. Systeme zur herstellung eines rückläufigen blutflusses in der halsschlagader
CA2910760C (en) 2007-12-04 2019-07-09 Muthiah Manoharan Targeting lipids
CA2707042A1 (en) 2007-12-10 2009-06-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor vii gene
US20090176729A1 (en) * 2007-12-14 2009-07-09 Alnylam Pharmaceuticals, Inc. Method of treating neurodegenerative disease
US20110052501A1 (en) * 2008-01-31 2011-03-03 Liat Dassa Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
WO2009099764A1 (en) * 2008-02-05 2009-08-13 Silk Road Medical, Inc. Interventional sheath with retention features
CN101983040A (zh) 2008-02-05 2011-03-02 丝绸之路医药公司 介入导管系统和方法
CA2715765A1 (en) * 2008-02-19 2009-08-27 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
KR101397407B1 (ko) 2008-03-05 2014-06-19 알닐람 파마슈티칼스 인코포레이티드 Ｅｇ5 및 ＶＥＧＦ 유전자의 발현을 억제하기 위한 조성물 및 방법
WO2009126933A2 (en) 2008-04-11 2009-10-15 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
JP2011523401A (ja) * 2008-04-29 2011-08-11 ワイス・エルエルシー 炎症を治療するための方法
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
WO2009136297A2 (en) * 2008-05-09 2009-11-12 Recopharma Ab Compositions and methods for inhibiting toxin a from clostridium difficile
US20090280104A1 (en) * 2008-05-09 2009-11-12 Recopharma Ab Compositions and methods for inhibiting shiga toxin and shiga-like toxin
JP2011523560A (ja) 2008-06-02 2011-08-18 ダナ−ファーバー キャンサー インスティテュート インク． Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
WO2010006973A2 (en) * 2008-07-15 2010-01-21 F. Hoffmann-La Roche Ag Compositions and methods for inhibiting expression of tgf-beta receptor genes
CA2731730C (en) 2008-07-23 2017-06-13 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
US8574245B2 (en) 2008-08-13 2013-11-05 Silk Road Medical, Inc. Suture delivery device
RU2011111748A (ru) 2008-08-29 2012-10-10 Сентокор Орто Байотек Инк. (Us) Маркеты и способы анализа и лечения язвенного колита и сходных заболеваний с использованием панели из 20 генов
EP3208337A1 (de) 2008-09-02 2017-08-23 Alnylam Pharmaceuticals, Inc. Zusammensetzungen zur kombinationshemmung der expression eines mutanten egfr und il-6
US8546554B2 (en) 2008-09-25 2013-10-01 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene
US9207242B2 (en) 2008-10-09 2015-12-08 The University Of Hong Kong Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
PT3335728T (pt) 2008-10-10 2020-02-19 Childrens Medical Center Vacina de trímero de envelope para hiv-1 bioquimicamente estabilizada
AU2009307677C1 (en) 2008-10-20 2022-09-22 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
US20120052066A1 (en) 2008-11-07 2012-03-01 Cesar Calderon Markers and methods for assessing and treating lupus patients susceptible to photoprovocation
EP2373382B1 (de) 2008-12-10 2017-02-15 Alnylam Pharmaceuticals, Inc. Auf gnaq zielende dsrna-zusammensetzungen und verfahren zur unterdrückung der expression
US9181315B2 (en) 2009-01-08 2015-11-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
CN102307996A (zh) 2009-02-03 2012-01-04 弗·哈夫曼-拉罗切有限公司 用于抑制ptp1b基因表达的组合物和方法
US20120041051A1 (en) 2009-02-26 2012-02-16 Kevin Fitzgerald Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
NZ594995A (en) 2009-03-12 2013-06-28 Alnylam Pharmaceuticals Inc LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES
WO2010110931A2 (en) 2009-03-23 2010-09-30 The Brigham And Women's Hospital, Inc. Glycoconjugate vaccines
US9675673B2 (en) * 2009-04-24 2017-06-13 Ingeneron Incorporated Transluminal delivery of oncoltyic viruses for cancer therapy
LT2424991T (lt) 2009-05-02 2018-09-25 Genzyme Corporation Neurodegeneracinių sutrikimų genų terapija
CN102427852A (zh) * 2009-05-15 2012-04-25 霍夫曼-拉罗奇有限公司 用于抑制糖皮质素受体(gcr)基因表达的组合物和方法
WO2010141752A1 (en) 2009-06-03 2010-12-09 Silk Road Medical, Inc. System and methods for controlling retrograde carotid arterial blood flow
EP4218794A3 (de) 2009-06-10 2023-09-13 New York University Immunologisches targeting pathologischer tau-proteine
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
WO2011005496A2 (en) 2009-06-22 2011-01-13 Massachusetts Eye & Ear Infirmary Islet1 (isl1) and hearing loss
ME01699B (me) 2009-07-02 2014-09-20 Musc Found For Res Dev Metode za stimulaciju regeneracije jetre
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
US10155099B2 (en) 2009-09-21 2018-12-18 Cook Regentec Llc Method for infusing stem cells
MX2012005151A (es) 2009-11-05 2012-08-23 Federico Ii University Of Naples Tratamiento de hemoglobinuria nocturna paroxismica, anemias hemoliticas y estados de enfermedad que involucran hemolisis intravascular y extravascular.
WO2011054939A2 (en) 2009-11-09 2011-05-12 F. Hoffmann-La Roche Ag Compositions and methods for inhibiting expression of kif10 genes
CA2778953C (en) 2009-11-13 2020-01-14 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
US20110152349A1 (en) 2009-12-18 2011-06-23 Anke Geick Compositions and methods for inhibiting expression of il-18 genes
AU2011207210A1 (en) 2010-01-22 2012-08-16 Dana-Farber Cancer Institute, Inc. Compositions,kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
US20110196016A1 (en) * 2010-02-05 2011-08-11 Anke Geick Compositions and Methods for Inhibiting Expression of IKK2 Genes
CN107098958B (zh) 2010-03-26 2021-11-05 达特茅斯大学理事会 Vista调节性t细胞介体蛋白、vista结合剂及其用途
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
EP3329924B1 (de) 2010-03-29 2021-05-05 Alnylam Pharmaceuticals, Inc. Dsrna-therapie für durch transthyretin (ttr) vermittelte augenamyloidose
EP2377888A1 (de) 2010-04-07 2011-10-19 Corimmun GmbH Fusionsprotein
US11020444B2 (en) * 2010-04-23 2021-06-01 Scicotec Gmbh Transluminal delivery of viruses for treatment of diseased tissue
US9522262B2 (en) * 2010-04-28 2016-12-20 Kimberly-Clark Worldwide, Inc. Medical devices for delivery of siRNA
KR101790815B1 (ko) 2010-04-28 2017-10-26 킴벌리-클라크 월드와이드, 인크. 세포성 상호작용이 향상된 나노패턴화 의료 기구
PT2563450T (pt) 2010-04-28 2017-08-28 Kimberly Clark Co Dispositivo para entrega de medicação para a artrite reumatóide
MX2012012567A (es) 2010-04-28 2012-11-21 Kimberly Clark Co Metodo para aumentar la permeabilidad de una barrera epitelial.
MX2012013233A (es) 2010-05-14 2013-05-20 Univ Colorado Regents Grupos que apuntan a receptor 2 de complemento (cr2) mejorados.
KR20130036276A (ko) 2010-06-22 2013-04-11 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 보체 결합 3의 C3d 조각에 대한 항체들
WO2012026820A2 (en) 2010-08-27 2012-03-01 Pantarhei Bioscience B.V. Immunotherapeutic method for treating prostate cancer
US9290760B2 (en) 2010-09-15 2016-03-22 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
US20120076736A1 (en) * 2010-09-17 2012-03-29 Rochester Institute Of Technology Host supported genetic biosensors
CN103391784A (zh) 2010-10-15 2013-11-13 纽约市哥伦比亚大学理事会 肥胖症-相关的基因和它们的蛋白和其用途
EP2630240A1 (de) 2010-10-18 2013-08-28 Arrowhead Research Corporation Zusammensetzungen und verfahren zur hemmung der expression von rrm2-genen
WO2012061537A2 (en) 2010-11-02 2012-05-10 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
WO2012064743A2 (en) 2010-11-08 2012-05-18 The Johns Hopkins University Methods for improving heart function
GB2485385A (en) 2010-11-12 2012-05-16 Univ Manchester Trimeric fusion protein comprising collagen and a prokaryotic/ viral trimerisation domain
WO2012068463A2 (en) 2010-11-18 2012-05-24 Beth Israel Deaconess Medicall Center, Inc. Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
US9198975B2 (en) 2010-12-01 2015-12-01 The University Of North Carolina At Chapel Hill Methods and compositions for targeting sites of neovascular growth
WO2012092299A1 (en) 2010-12-27 2012-07-05 Brown University Therapeutic and diagnostic methods involving biglycan and utrophin
US11458290B2 (en) 2011-05-11 2022-10-04 Ekos Corporation Ultrasound system
US9592398B2 (en) 2011-05-12 2017-03-14 Medtronic, Inc. Leadless implantable medical device with osmotic pump
EP2723351B1 (de) 2011-06-21 2018-02-14 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur hemmung der expression von protein-c (proc)-genen
RU2631805C2 (ru) 2011-06-21 2017-09-26 Элнилэм Фармасьютикалз, Инк. Композиции и способы ингибирования экспрессии генов аполипопротеина с-iii (арос3)
PT2726613T (pt) 2011-06-30 2018-10-26 Arrowhead Pharmaceuticals Inc Composições e métodos para inibição da expressão de genes do vírus da hepatite b
US10093705B2 (en) 2011-09-13 2018-10-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using FNDC5
CA2850514A1 (en) 2011-10-14 2013-04-18 Genentech, Inc. Peptide inhibitors of bace1
US10378060B2 (en) 2011-10-14 2019-08-13 Dana-Farber Cancer Institute, Inc. ZNF365/ZFP365 biomarker predictive of anti-cancer response
US9796974B2 (en) 2011-11-18 2017-10-24 Alnylam Pharmaceuticals, Inc. Modified RNAi agents
SG10201604810UA (en) * 2012-02-07 2016-08-30 Global Bio Therapeutics Inc Compartmentalized method of nucleic acid delivery and compositions and uses thereof
EP3456742A1 (de) 2012-02-15 2019-03-20 Novo Nordisk A/S Peptidoglycanerkennungsprotein 1 bindende antikörper
PL2814844T3 (pl) 2012-02-15 2017-12-29 Novo Nordisk A/S Przeciwciała wiążące i blokujące receptor aktywujący wykazujący ekspresję na komórkach szpikowych -1 (trem-1)
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
HUE040127T2 (hu) 2012-03-29 2019-02-28 Univ Columbia Eljárások hajhullási rendellenességek kezelésére
US20150190532A1 (en) 2012-04-04 2015-07-09 The Trustees Of Columbia University In The City Of New York Smooth muscle specific inhibition for anti-restenotic therapy
JP6499578B2 (ja) 2012-06-05 2019-04-10 マフィン・インコーポレイテッドＭｕｆｆｉｎ Ｉｎｃｏｒｐｏｒａｔｅｄ 細胞療法に有用なカテーテルシステム及び方法
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
WO2014018851A1 (en) 2012-07-26 2014-01-30 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
WO2014022739A2 (en) 2012-08-03 2014-02-06 Alnylam Pharmaceuticals, Inc. Modified rnai agents
ES2771324T3 (es) 2012-08-03 2020-07-06 Dana Farber Cancer Inst Inc Usos médicos de agentes que modulan la activación de las células inmunitarias y métodos de detección correspondientes
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
CA2884704C (en) 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
CN105377288B (zh) 2012-11-05 2019-11-15 达纳-法伯癌症研究所股份有限公司 Xbp1、cd138和cs1肽的组合物制备药物的用途
US9340787B2 (en) 2012-11-15 2016-05-17 Yale University Compositions and methods of using micro RNAs
EP2851086A1 (de) 2013-09-20 2015-03-25 Sanofi Serpine: Verfahren zur therapeutischen ß-Zellen-Regeneration und Funktion
WO2014128257A1 (en) 2013-02-22 2014-08-28 Sanofi Serpins: methods of therapeutic beta-cell regeneration and function
EP2769732A1 (de) 2013-02-22 2014-08-27 Sanofi Serpine: Verfahren zur therapeutischen Beta-Zellen-Regeneration und Funktion
US9637534B2 (en) 2013-03-13 2017-05-02 Genzyme Corporation Fusion proteins comprising PDGF and VEGF binding portions and methods of using thereof
KR20150129847A (ko) 2013-03-15 2015-11-20 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 융합 단백질 및 이들의 방법
WO2014176259A1 (en) 2013-04-22 2014-10-30 Icahn School Of Medicine At Mount Sinai Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis
AU2013388083B2 (en) 2013-05-01 2019-08-22 Genzyme Corporation Compositions and methods for treating spinal muscular atrophy
WO2014191630A2 (en) 2013-05-28 2014-12-04 Helsingin Yliopisto Non-human animal model encoding a non-functional manf gene
AU2014275166B2 (en) 2013-06-06 2020-09-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using PD-L1 isoforms
WO2014207578A2 (en) 2013-06-13 2014-12-31 Orgenesis Ltd. Cell populations, methods of transdifferention and methods of use thereof
WO2015017529A2 (en) 2013-07-31 2015-02-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
MX2016001667A (es) 2013-08-08 2016-11-07 Global Bio Therapeutics Inc Dispositivo de sujecion para procedimientos minimamente invasivos y usos del mismo.
MX366880B (es) 2013-08-08 2019-07-29 Global Bio Therapeutics Inc Dispositivo de inyección para procedimientos mínimamente invasivos y usos del mismo.
EP3049442A4 (de) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Verfahren zur behandlung von blutkrebs
WO2015066190A1 (en) 2013-10-29 2015-05-07 President And Fellows Of Harvard College Methods and compositions for inhibting oxidative stress
EP3074037B1 (de) 2013-11-27 2020-10-07 Inis Biotech LLC Verfahren zur modulierung der angiogenese von auf eine anti-vegf behandlung refraktären karzinomen
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
HRP20220748T1 (hr) 2013-12-24 2022-09-02 Janssen Pharmaceutica Nv Anti-vista antitijela i fragmenti
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2015106128A2 (en) 2014-01-09 2015-07-16 Alnylam Pharmaceuticals, Inc. MODIFIED RNAi AGENTS
WO2015164743A2 (en) 2014-04-24 2015-10-29 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
US20170190762A1 (en) 2014-06-11 2017-07-06 Beth Israel Deaconess Medical Center, Inc. Alpha1 -antitrypsin compositions and methods of treating autoimmune diseases
CA2951885C (en) 2014-06-11 2023-07-04 Kathy A. Green Use of vista agonists and antagonists to suppress or enhance humoral immunity
WO2016011203A1 (en) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
PE20170192A1 (es) 2014-07-17 2017-03-16 Novo Nordisk As Mutagenesis dirigida al sitio de anticuerpos receptor desencadenante expresado en las meloid tipo 1 (trem-1) para reducir la viscosidad
KR102494171B1 (ko) 2014-08-20 2023-02-02 알닐람 파마슈티칼스 인코포레이티드 변형 이중-가닥 rna 제제
US20170246259A1 (en) 2014-09-10 2017-08-31 Georgetown University Compositions and Methods of Using Interleukin-4 Induced Gene 1 (IL-4I1)
PL3110447T3 (pl) 2014-09-16 2020-10-19 Synermore Biologics Co., Ltd. Przeciwciało anty-EGFR i jego zastosowania
US10092742B2 (en) 2014-09-22 2018-10-09 Ekos Corporation Catheter system
WO2016057367A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
US10806773B2 (en) 2014-10-09 2020-10-20 Dana-Farber Cancer Institute, Inc. Multiple-variable IL-2 dose regimen for treating immune disorders
US20170304459A1 (en) 2014-10-10 2017-10-26 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhalation delivery of conjugated oligonucleotide
JP7305300B2 (ja) 2014-11-05 2023-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 併用免疫療法
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
WO2016090347A1 (en) 2014-12-05 2016-06-09 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
WO2016094273A1 (en) 2014-12-08 2016-06-16 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
WO2016105517A1 (en) 2014-12-23 2016-06-30 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
MA41296A (fr) 2014-12-30 2017-11-07 Orgenesis Ltd Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
CA3014427A1 (en) 2015-02-13 2016-08-18 Icahn School Of Medicine At Mount Sinai Rna containing compositions and methods of their use
WO2016138287A1 (en) 2015-02-25 2016-09-01 Washington University METHODS TO DETECT MOTOR NEURON DISEASE COMPRISING MICRO-RNAs
CA2977532A1 (en) 2015-03-06 2016-09-15 Dana-Farber Cancer Institute, Inc. Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
EP3735982A1 (de) 2015-03-10 2020-11-11 The University of Massachusetts Abzielung auf gdf6 und bmp-signalisierung für antimelanomtherapie
ES2901455T3 (es) 2015-04-03 2022-03-22 Univ Massachusetts Compuestos oligonucleotídicos para el tratamiento de preeclampsia y otros trastornos angiogénicos
WO2016161374A1 (en) 2015-04-03 2016-10-06 University Of Massachusetts Oligonucleotide compounds for targeting huntingtin mrna
US20180104289A1 (en) 2015-04-08 2018-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Viral gene therapy as treatment for cholesterol storage disease or disorder
KR20180015145A (ko) 2015-05-05 2018-02-12 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 핵산-양이온성 중합체 조성물 및 그의 제조 및 사용 방법
EP3294332A4 (de) 2015-05-14 2018-12-26 Joslin Diabetes Center, Inc. Retinolbindendes protein 3 (rbp3) als schutzfaktor bei nicht diabetischer netzhautdegeneration
EP3307388B1 (de) 2015-06-10 2022-06-22 Ekos Corporation Ultraschallkatheter
DK3313882T3 (da) 2015-06-24 2020-05-11 Janssen Pharmaceutica Nv Anti-VISTA antistoffer og fragmenter
EP3328376A4 (de) 2015-07-31 2019-03-13 The Johns Hopkins University Verfahren und zusammensetzung zur behandlung metabolischer umprogrammierungserkrankungen
US10842763B2 (en) 2015-07-31 2020-11-24 The Johns Hopkins University Methods for cancer and immunotherapy using prodrugs of glutamine analogs
CN112920092B (zh) 2015-07-31 2024-04-26 约翰霍普金斯大学 谷氨酰胺类似物的前药
CA2991639A1 (en) 2015-08-07 2017-02-16 Arrowhead Pharmaceuticals, Inc. Rnai therapy for hepatitis b virus infection
WO2017030973A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
EP3347486A4 (de) 2015-09-09 2019-06-19 The Trustees of Columbia University in the City of New York Reduktion von er-mam-lokalisierten app-c99 und verfahren zur behandlung der alzheimer-krankheit
WO2017066796A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
WO2017066561A2 (en) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
WO2017066712A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
US10188750B1 (en) 2015-10-23 2019-01-29 University Of South Florida Self-replicating cell selective gene delivery compositions, methods, and uses thereof
EP3368157B1 (de) 2015-10-29 2022-06-29 Dana-Farber Cancer Institute, Inc. Verfahren zur identifizierung, beurteilung, prävention und behandlung von stoffwechselerkrankungen mit verwendung von pm20d1 und n-lipidierten aminosäuren
EP3377086B1 (de) 2015-11-19 2024-05-01 The Brigham and Women's Hospital, Inc. Lymphozytenantigen cd5-like(cd5l)-interleukin 12b (p40)-heterodimere in der immunität
CN108697813B (zh) 2016-01-13 2024-01-16 勃林格殷格翰动物保健美国公司 用于治疗哺乳动物内骨关节炎和相关关节病症的表达骨保护性基因、包括has2和润滑素的重组aav载体
EP3408391A4 (de) 2016-01-31 2019-08-28 University of Massachusetts Verzweigte oligonukleotide
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
US20210309965A1 (en) 2016-03-21 2021-10-07 Dana-Farber Cancer Institute, Inc. T-cell exhaustion state-specific gene expression regulators and uses thereof
US20210017281A1 (en) 2016-04-15 2021-01-21 Immunext, Inc. Anti-human vista antibodies and use thereof
CA2932910A1 (en) 2016-06-14 2017-12-14 Entos Pharmaceuticals Inc. Methods for diagnosing and treating metastatic cancer
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
WO2018031933A2 (en) 2016-08-12 2018-02-15 University Of Massachusetts Conjugated oligonucleotides
WO2018057618A1 (en) 2016-09-20 2018-03-29 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators
WO2018071814A1 (en) 2016-10-14 2018-04-19 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder
US11007254B2 (en) 2016-10-17 2021-05-18 Musc Foundation For Research Development Compositions and methods for treating central nervous system injury
WO2018085836A1 (en) 2016-11-07 2018-05-11 Colorado State University Research Foundation Anti-hiv peptides
US10443055B2 (en) 2016-12-22 2019-10-15 Beth Israel Deaconess Medical Center Compounds that target MYC microRNA responsive elements for the treatment of MYC-associated cancer
US11795201B2 (en) 2017-04-14 2023-10-24 University Of Massachusetts Brown fat-selective adipokines
WO2018207179A1 (en) 2017-05-08 2018-11-15 Orgenesis Ltd. Transdifferentiated cell populations and methods of use thereof
EP3634496A4 (de) 2017-06-06 2021-09-08 Dana-Farber Cancer Institute, Inc. Verfahren zur sensibilisierung von krebszellen gegen t-zell-vermittelte abtötung mittels modulierung von molekularen signalwegen
CA3068010A1 (en) 2017-06-20 2018-12-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Codon-optimized human npc1 genes for the treatment of niemann-pick type c1 deficiency and related conditions
TN2019000308A1 (en) 2017-07-06 2021-05-07 Arrowhead Pharmaceuticals Inc RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
AU2018326805B2 (en) 2017-09-01 2023-11-30 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to BCMA and TACI antigens for treatment of cancer
EP3460057A1 (de) 2017-09-22 2019-03-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Kdac varianten und deren nutzung
WO2019071116A1 (en) 2017-10-05 2019-04-11 Epivax, Inc. T REGULATORY LYMPHOCYTE EPITOPES
US11597932B2 (en) 2017-12-21 2023-03-07 Alnylam Pharmaceuticals, Inc. Chirally-enriched double-stranded RNA agents
MA52190A (fr) 2018-04-02 2021-02-17 Bristol Myers Squibb Co Anticorps anti-trem-1 et utilisations associées
WO2019195449A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
CA3102182A1 (en) 2018-06-01 2019-12-05 Sanofi Combination therapy for treating hepatitis b virus infection
EP3810184A2 (de) 2018-06-21 2021-04-28 University of Rochester Verfahren zur behandlung oder hemmung des auftretens von morbus huntington
MX2021001590A (es) 2018-08-10 2021-07-02 Univ Massachusetts Oligonucleótidos modificados dirigidos a snp.
EP3626820A1 (de) 2018-09-20 2020-03-25 Fundación Imdea Nanociencia Krebsbekämpfende zusammensetzungen mit mirna-imitatoren und verwendungen davon
US20220056444A1 (en) 2018-12-05 2022-02-24 Empirico Inc. Process to inhibit or eliminate eosinophilic diseases of the airway and related conditions
US11116778B2 (en) 2019-01-15 2021-09-14 Empirico Inc. Prodrugs of ALOX-15 inhibitors and methods of using the same
WO2020167822A2 (en) 2019-02-13 2020-08-20 University Of Rochester Gene networks that mediate remyelination of the human brain
WO2020181142A1 (en) 2019-03-06 2020-09-10 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
MX2021011468A (es) 2019-03-21 2021-12-15 Vectores de virus adenoasociados recombinantes.
KR20210145213A (ko) 2019-03-29 2021-12-01 다이서나 파마수이티컬, 인크. Kras 관련 질환 또는 장애를 치료하기 위한 조성물 및 방법
EP3962529A4 (de) 2019-04-30 2023-11-01 Dana-Farber Cancer Institute, Inc. Verfahren zur krebsbehandlung unter verwendung von kombinationen aus anti-cx3cr1 und immuncheckpoint-blockierungsreagenzien
CN114072501A (zh) 2019-05-06 2022-02-18 马萨诸塞大学 抗c9orf72寡核苷酸及相关方法
BR112022002307A2 (pt) 2019-08-09 2022-06-28 Univ Massachusetts Oligonucleotídeos quimicamente modificados que têm como alvo snps
WO2021076925A1 (en) 2019-10-17 2021-04-22 Stridebio, Inc. Adeno-associated viral vectors for treatment of niemann-pick disease type c
US20230028476A1 (en) 2019-12-03 2023-01-26 Evotec International Gmbh Interferon-associated antigen binding proteins for use in treating hepatitis b infection
IL293450A (en) 2019-12-03 2022-07-01 Evotec Int Gmbh Interferon-related antigen-binding proteins and uses thereof
WO2021141733A1 (en) 2020-01-07 2021-07-15 The Procter & Gamble Company Method of modulating a fibrotic condition
KR20230058045A (ko) 2020-07-20 2023-05-02 다나-파버 캔서 인스티튜트 인크. 코로나바이러스 감염을 치료 및 예방하기 위한 방법 및 조성물
US12006550B2 (en) 2020-10-12 2024-06-11 University Of South Carolina Targeting treatment for ADAM30 in pathological cells
US20230374599A1 (en) 2020-10-19 2023-11-23 Alexander Gusev Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
US20240158864A1 (en) 2021-01-25 2024-05-16 Dana-Farber Cancer Institute, Inc. Methods and compositions for identifying neuroendocrine prostate cancer
CN117042767A (zh) 2021-02-11 2023-11-10 丹娜法伯癌症研究院 使用sting激动剂治疗癌症的方法
MX2023010238A (es) 2021-03-02 2023-12-05 Dana Farber Cancer Inst Inc Métodos para tratar trastornos de glóbulos rojos.
WO2022240741A1 (en) 2021-05-12 2022-11-17 Dana-Farber Cancer Institute, Inc. Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
JP2024521958A (ja) 2021-06-09 2024-06-04 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング コロナウイルス感染の処置又は予防のための使用のためのインターフェロン会合抗原結合性タンパク質
JP2024523509A (ja) 2021-06-23 2024-06-28 ユニバーシティー オブ マサチューセッツ 子癇前症及び他の血管新生障害の治療のために最適化された抗ｆｌｔ１オリゴヌクレオチド化合物
WO2023280988A1 (en) 2021-07-09 2023-01-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving relaxation of striated myocytes
WO2023081633A1 (en) 2021-11-02 2023-05-11 University Of Rochester Tcf7l2 mediated remyelination in the brain
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
WO2023158732A1 (en) 2022-02-16 2023-08-24 Dana-Farber Cancer Institute, Inc. Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof
WO2024126293A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection
WO2024126294A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of parainfluenza virus infection
WO2024126289A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351337A (en) * 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US4182330A (en) * 1977-07-25 1980-01-08 Alza Corporation Means for administering amphipathic medicament
US4332893A (en) * 1980-06-13 1982-06-01 Rosenberg Ralph A Process for the production of an insulin-producing cell line of pancreatic beta cells
US4353888A (en) * 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4636195A (en) * 1982-04-02 1987-01-13 Harvey Wolinsky Method and apparatus for removing arterial constriction
US4824436A (en) * 1985-04-09 1989-04-25 Harvey Wolinsky Method for the prevention of restenosis
EP0273085A1 (de) * 1986-12-29 1988-07-06 IntraCel Corporation Verfahren zur Einführung fremder Nukleinsäuren in eukaryotische Zellen
DE3742049A1 (de) * 1987-12-11 1989-06-22 Theurer Karl Eugen Herstellung und anwendung von impfstoffen und diagnostika fuer virus- und krebserkrankungen
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
DE69032284T2 (de) † 1989-03-21 1998-10-08 Vical, Inc., San Diego, Calif. Expression von exogenen polynukleotidsequenzen in wirbeltieren
WO1990011734A1 (en) * 1989-03-31 1990-10-18 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5049132A (en) * 1990-01-08 1991-09-17 Cordis Corporation Balloon catheter for delivering therapeutic agents
US7331366B1 (en) 2005-05-31 2008-02-19 Patterson Brian A Money and card holding assembly

Also Published As

Publication number Publication date
JP3712409B2 (ja) 2005-11-02
US5328470A (en) 1994-07-12
EP1213032B1 (de) 2008-02-13
DK0591385T3 (da) 2002-06-24
DE1213032T1 (de) 2003-02-06
EP1927368A3 (de) 2008-06-11
WO1993000051A1 (en) 1993-01-07
JP2001213806A (ja) 2001-08-07
EP1927368A2 (de) 2008-06-04
EP0591385B1 (de) 2002-03-20
EP1213032A1 (de) 2002-06-12
EP0591385A1 (de) 1994-04-13
DE69232497T2 (de) 2002-11-14
CA2112376A1 (en) 1993-01-07
EP1013287A2 (de) 2000-06-28
JPH06509328A (ja) 1994-10-20
EP1013287A3 (de) 2000-07-05
JP2002239010A (ja) 2002-08-27
ATE214576T1 (de) 2002-04-15
EP0591385A4 (en) 1996-11-27
ES2301602T3 (es) 2008-07-01
ATE385810T1 (de) 2008-03-15

Similar Documents

Publication Publication Date Title
DE69232497D1 (de) Behandlung von krankheiten durch ortsspezifische instillation von zellen oder ortsspezifische transformation von zellen sowie ausrüstung dafür
Achauer A serious complication following medical-grade silicone injection of the face
Raper et al. Profound reversible myocardial depression after anaphylaxis
Waikakul et al. Prognostic factors for major limb re-implantation at both immediate and long-term follow-up
Gura Estrogen: key player in heart disease among women
Rees et al. Lentiginosis and left atrial myxoma.
Quinn et al. Coronary artery bed photoscanning using radioiodine albumin macroaggregates (RAMA)
Palande et al. Surgical decompression of posterior tibial neurovascular complex in treatment of certain chronic plantar ulcers and posterior tibial neuritis in leprosy
Otom et al. Ischaemic spinal cord injury following a coronary angiogram: a case report
Antoniades Hypoglycaemic effect of adipose-tissue extracts in adrenalectomised rats
Cantril et al. Roentgen Therapy in Gas Bacillus Infection: Report of Nine Cases with Recovery
Killip Coronary bypass surgery. Where we stand today.
Andersen Brachialis Seldinger puncture with use of introducer sheath
RU2152038C1 (ru) Биоинженерный способ восстановления функций мозга
Pandya Surgery on the peripheral nerves in leprosy
Fournier et al. Selective ergonovine-induced coronary artery spasm and ST-segment alternans after blunt thoracic trauma
Harris et al. Bundle Branch Block
Harris et al. Bundle Branch Block
RU1780741C (ru) Способ лечени деформирующего остеоартроза
Charlesworth The role of minimally invasive surgery
Freiberg HELIOTHERAPY AT LOW ALTITUDES: ITS SIGNIFICANCE AND TECHNIC
Riggs et al. Management of necrotic wounds as a complication of histiocytosis X
Piacquadio Dermatology: Current Concerns With Collagen for Soft Tissue Augmentation
Delano A Study in the Internal Therapeutics of Radium
Grobin The kidney and high blood pressure

Legal Events

Date Code Title Description
8363 Opposition against the patent
8339 Ceased/non-payment of the annual fee